Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel B Costa

Showing results (61-70 of 175) with videos related to

Pageof 18
Sort By:
Current Oncology Reports|July 13, 2010
Molecular testing in lung cancer: the time is nowHaiying Cheng, Xunhai Xu, Daniel B Costa, et al.
Journal of Alternative and Complementary Medicine (New York, N.Y.)|February 6, 2013
Safety of cupping during bevacizumab therapySamuel J Klempner, Daniel B Costa, Peggy A Wu, et al.
Clinical Lung Cancer|October 24, 2019
Extensive-Stage Small-Cell Lung Cancer With Sustained Complete Response to Single-Agent Nivolumab and Immune-Related DermatitisPage Widick, Ritu R Gill, Charlene Mantia, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 29, 2018
Authors' ResponseMatthew P Cheng, Francisco M Marty, Daniel B Costa, et al.
The Oncologist|September 24, 2020
Clinical Benefit of Tyrosine Kinase Inhibitors in Advanced Lung Cancer with EGFR-G719A and Other Uncommon EGFR MutationsKartik Sehgal, Deepa Rangachari, Paul A VanderLaan, et al.
Cells|December 24, 2021
EGFR-D770>GY and Other Rare EGFR Exon 20 Insertion Mutations with a G770 Equivalence Are Sensitive to Dacomitinib or Afatinib and Responsive to EGFR Exon 20 Insertion Mutant-Active Inhibitors in Preclinical Models and Clinical ScenariosIkei S Kobayashi, Hollis Viray, Deepa Rangachari, et al.
JTO Clinical and Research Reports|March 17, 2021
Preclinical characterization of mobocertinib highlights the putative therapeutic window of this novel EGFR inhibitor to EGFR exon 20 insertion mutationsPedro E N S Vasconcelos, Ikei S Kobayashi, Susumu S Kobayashi, et al.
Journal of the National Medical Association|August 10, 2006
Case of fatal sickle cell intrahepatic cholestasis despite use of exchange transfusion in an African-American patientDaniel B Costa, Rebecca A Miksad, Michael S Buff, et al.
Journal for Immunotherapy of Cancer|June 26, 2020
Small cell transformation of non-small cell lung cancer on immune checkpoint inhibitors: uncommon or under-recognized?Kartik Sehgal, Andreas Varkaris, Hollis Viray, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 24, 2010
KRAS mutation analysis helps to differentiate between pulmonary metastasis from colon adenocarcinoma in situ and primary lung adenocarcinomaTaylor M Ortiz, David W Cohen, Michael S Kent, et al.
Pageof 18

Showing results (61-70 of 175) with videos related to

Sort By:
Pageof 18
Current Oncology Reports|July 13, 2010
Molecular testing in lung cancer: the time is nowHaiying Cheng, Xunhai Xu, Daniel B Costa, et al.
Journal of Alternative and Complementary Medicine (New York, N.Y.)|February 6, 2013
Safety of cupping during bevacizumab therapySamuel J Klempner, Daniel B Costa, Peggy A Wu, et al.
Clinical Lung Cancer|October 24, 2019
Extensive-Stage Small-Cell Lung Cancer With Sustained Complete Response to Single-Agent Nivolumab and Immune-Related DermatitisPage Widick, Ritu R Gill, Charlene Mantia, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 29, 2018
Authors' ResponseMatthew P Cheng, Francisco M Marty, Daniel B Costa, et al.
The Oncologist|September 24, 2020
Clinical Benefit of Tyrosine Kinase Inhibitors in Advanced Lung Cancer with EGFR-G719A and Other Uncommon EGFR MutationsKartik Sehgal, Deepa Rangachari, Paul A VanderLaan, et al.
Cells|December 24, 2021
EGFR-D770>GY and Other Rare EGFR Exon 20 Insertion Mutations with a G770 Equivalence Are Sensitive to Dacomitinib or Afatinib and Responsive to EGFR Exon 20 Insertion Mutant-Active Inhibitors in Preclinical Models and Clinical ScenariosIkei S Kobayashi, Hollis Viray, Deepa Rangachari, et al.
JTO Clinical and Research Reports|March 17, 2021
Preclinical characterization of mobocertinib highlights the putative therapeutic window of this novel EGFR inhibitor to EGFR exon 20 insertion mutationsPedro E N S Vasconcelos, Ikei S Kobayashi, Susumu S Kobayashi, et al.
Journal of the National Medical Association|August 10, 2006
Case of fatal sickle cell intrahepatic cholestasis despite use of exchange transfusion in an African-American patientDaniel B Costa, Rebecca A Miksad, Michael S Buff, et al.
Journal for Immunotherapy of Cancer|June 26, 2020
Small cell transformation of non-small cell lung cancer on immune checkpoint inhibitors: uncommon or under-recognized?Kartik Sehgal, Andreas Varkaris, Hollis Viray, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 24, 2010
KRAS mutation analysis helps to differentiate between pulmonary metastasis from colon adenocarcinoma in situ and primary lung adenocarcinomaTaylor M Ortiz, David W Cohen, Michael S Kent, et al.
Pageof 18